ArticleFrontiers in genetics2026
A novel prognostic model for ovarian cancer: construction, validation, and therapeutic insights.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer (OV) is the most lethal gynaecological malignancy worldwide. Palmitoylation, a reversible post-translational lipid modification, has been implicated in tumourigenesis, growth, metastasis and apoptosis across multiple cancers. However, its impact on immune infiltration, therapeutic response and clinical outcomes in ovarian cancer remains insufficiently explored. Methods: We obtained transcriptome data and clinical information pertaining to ovarian cancer from the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO) databases. A prognostic model based on palmitoylation-related genes was constructed using univariate Cox and Lasso-Cox regression for feature selection. The predictive performance of the model was assessed via Kaplan-Meier (KM) survival analysis and receiver operating characteristic (ROC) curve evaluation. Results: We developed a five-gene prognostic prediction model utilizing palmitoylation-related genes derived from TCGA samples of epithelial ovarian cancer patients. The validity of this model was confirmed using patient samples from both TCGA and GEO datasets. KM analysis demonstrated that our prognostic model effectively distinguished between high-risk and low-risk groups, correlating with poorer or more favorable outcomes respectively. According to ROC curve analysis, our model exhibited superior predictive accuracy compared to traditional clinical factors alone. Additionally, analyses regarding immune cell infiltration, expression levels of immune checkpoints, as well as drug sensitivity further support potential treatment strategies for ovarian cancer. Conclusion: The prognostic model developed in this study has the potential to enhance our understanding of the role of palmitic acid-related genes in ovarian cancer, providing new insights into prognosis prediction and treatment strategies for patients with ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.